88 results about "Transmembrane protein" patented technology

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.

The invention discloses a preparation method of a monomeric protein and hydrophobic transmembrane protein complex, which comprises the following steps: 1) preparing a protein A containing the monomeric protein, the C end of the monomeric protein in the protein A having a connection sequence for connecting with the hydrophobic transmembrane protein; the connecting sequence comprises at least two amino acids; preparing a protein B containing a hydrophobic transmembrane protein monomer; and 2) connecting the protein A with the protein B, and polymerizing the hydrophobic transmembrane protein monomers in the plurality of protein B to form the hydrophobic transmembrane protein, thereby obtaining the monomeric protein and hydrophobic transmembrane protein complex.

The invention belongs to the technical field of medical chemistry, and particularly relates to a targeted protein degradation compound containing an SYVN1 binding compound and application of the targeted protein degradation compound. According to the invention, a series of compounds interacting with SYVN1 are found, and the compounds can be used as'warheads' to participate in ERAD and effectively degrade transmembrane protein targets. Based on the SYVN1 binding compound, a new TPD technology for hijacking ERAD is established, and a brand new platform is provided for processing TMSPs and other proteins which are difficult to target by the current TPD technology. A SYVN1 interaction compound is further connected with a known ligand interacting with a protein target through a chemical linker, a series of ERADEC molecules are generated, the molecules can significantly degrade target protein, and a new possibility is provided for targeted degradation of drugs.

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

The present invention provides a long-acting dual-target chimeric antigen receptor, nucleic acid molecule, recombinant vector, cell, and application thereof. The dual-target chimeric antigen receptor comprises two independent transmembrane protein chains, wherein the first CAR chain targets a scFv of the first target, and the intracellular signal comprises a second signal and an intracellular transduction signal or only an intracellular transduction signal; the second CAR chain targets a scFv of the second target, and the intracellular signal comprises a costimulatory signal and a JAK enzyme activation transduction domain. The CAR-T cells prepared by the present invention have a strong and persistent killing effect on tumor cells that simultaneously express the first and second targets, and can be used for the anti-tumor treatment of solid tumors.

The present application relates to the field of biotechnology, in particular to a kit based on functionalized magnetic beads and application thereof in the field of stem cells. The functionalized magnetic beads of the present application are loaded with extracellular matrix proteins on the surface, and the extracellular matrix proteins are selected from collagen. The functionalized magnetic beads of the present application realize efficient capture and enrichment of collagen-bound transmembrane proteins, combined with mass spectrometry identification, and are suitable for screening stem cell transmembrane proteins, studying the action sites of stem cells and matrix, or developing drugs targeting stem cells. The kit and method of the present application have the technical advantages of simple operation, good stability and strong specificity, and provide a powerful tool for systematic study of the cell-matrix interaction mechanism mediated by stem cell transmembrane proteins.

Methods and compositions for treating a corneal wound and / or increasing a population of limbal epithelial stem cells (LESCs) and / or early transit amplifying cells (eTAs) in the limbal epithelium of a subject in need thereof. The methods can include administering a therapeutic agent to the subject that: i) results in an increase in concentration of IFITM1 (Interferon Induced transmembrane Protein 1) in the limbal epithelium of the subject; and / or ii) results in a decrease in concentration of OVOL1 (Ovo Like Zinc Finger 1) in the limbal epithelium of the subject. Also provided are adeno-associated viruses (AAVs). The AAVs comprise a heterologous nucleic acid sequence encoding IFITM1 or a variant thereof, operably linked to a regulatory sequence.

The application discloses a kind of bionic transmembrane protein affinity chromatography column and its preparation method and application.The system (iSTAC) realizes the in-situ construction of transmembrane protein in highly bionic dynamic microenvironment by integrating cell-free protein synthesis, functional mesoporous silica modification and amphiphilic (AH) peptide stabilized planar lipid bilayer technology.The core is to use long-chain PEG-24 crosslinking agent to retain lipid bilayer on the surface of silica gel, provide sufficient conformational dynamic space for multi-transmembrane protein, and introduce AH peptide to repair membrane defects, ensure that the receptor realizes directional embedding while maintaining natural functional attributes.The preparation cycle is shortened from 168 hours to 5 hours, which significantly improves the efficiency of targeted drug screening and in-situ analysis of binding sites.Using this platform, 5-HT 1A Receptor agonists crocin I and crocin II with anti-insomnia and neuroprotective effects are successfully screened from saffron, and the action site is accurately depicted.

The application discloses an exosome drug delivery system with anti-phagocytosis and tumor targeting ability as well as a preparation method and application thereof. A tumor targeting group is flexibly connected to the outside of the cell membrane of a transmembrane protein with anti-phagocytosis ability through a linker of a fusion protein. A fusion gene sequence is designed and inserted into an expression vector to form a fusion expression vector, which is integrated into the chromosome of a cell to be modified to obtain an engineered cell stably expressing the fusion protein, which is used for secreting engineered exosomes. The cell to be modified includes a naked cell (an immortalized cell line, a primary cell), an engineered cell stably expressing a therapeutic nucleic acid molecule or a protein. The exosomes produced by the former cell can further package the therapeutic molecules to treat tumors, and the exosomes produced by the latter cell can be directly used for treating tumors after being separated, purified and collected. The half-life of the engineered exosomes produced by the application is significantly prolonged in the body, the treatment effect is improved, and the exosomes show strong tumor targeting and anti-tumor effects in vivo and in vitro.

The application provides a screening method of human amniotic membrane mesenchymal stem cells (hAMSCs) with bone regeneration promoting potential, and uses the protein level of transmembrane protein 119 (TMEM119) as a functional index of the bone regeneration promoting ability of the hAMSCs, and uses an enzyme-linked immunosorbent assay (ELISA) to detect the TMEM119 protein concentration in a lysis solution prepared from 1×10 7 The application uses the TMEM119 protein concentration not lower than 15000 pg / mL as a screening standard of the hAMSCs with bone regeneration promoting potential, and screens the hAMSCs with significant bone regeneration promoting potential from different batches of hAMSCs, so that the hAMSCs meeting the screening standard of the application have obvious bone formation promoting potential, and the technical problem that the hAMSCs with bone regeneration promoting potential are difficult to be accurately identified and screened in clinical transformation is solved.

The invention discloses a multi-source vegetable outer vesicle composition as well as a preparation method and application thereof. The multi-source vegetable outer vesicle composition is prepared from outer vesicles extracted from spinach leaves, ginger tubers, broccoli buds, bitter gourd fruits and celery stems. The spinach leaves, the ginger tubers, the broccoli flower buds, the bitter gourd fruits and the celery stems are mixed according to the fresh weight ratio of (3-5): (1-2): (2-3): (1-1.5): (2-4), and low-temperature homogenization, centrifugation and ultrafiltration purification are performed to obtain the spinach-ginger-containing beverage. The particle size of the multisource vegetable outer vesicle composition is 100-200 nm, and the multisource vegetable outer vesicle composition comprises transmembrane protein TET8 and membrane anchoring protein ANNEXIN, and further comprises active ingredients of miR159a, miR166a, quercetin and kaempferol. The outer vesicle can target a PPAR gamma / FAS pathway and regulate and control lipolysis and metabolism reprogramming of fat cells; meanwhile, an Nrf2 pathway is activated, free radicals are removed, oxidative stress injury is inhibited, and metabolic diseases such as obesity, type II diabetes mellitus and non-alcoholic fatty liver disease can be effectively improved.

The invention discloses a preparation method of a nano-enzyme preparation as well as a product and application of the nano-enzyme preparation. The synthesis method of the nano-enzyme preparation comprises the following steps: mixing a transmembrane protein solution and a solution containing one or more nano-enzymes to prepare the nano-enzyme preparation. The nano-enzyme can target a disease site, and on one hand, the nano-enzyme removes active oxygen and active nitrogen species on the disease site; on the other hand, the nano-enzyme can be combined with cytokines of disease parts, the promotion effect of the cytokines on diseases is inhibited, and the effect of preventing and treating colitis and colitis-related colon cancer diseases is achieved. The nano-enzyme developed by the invention not only can relieve oxidative stress of diseases, but also can reduce the pro-inflammatory and tumor-promoting effects of cytokines, and can effectively treat colitis-related colon cancer caused by deterioration of colitis.

Disclosed herein is an artificial transmembrane protein for use in a biomolecule detection device for detecting intracellular or intravesicular biomolecule interactions, the artificial transmembrane protein comprising an extracellular or extravesicular binding structure, a hydrophobic transmembrane domain, and an intracellular or intravesicular domain having an intracellular or intravesicular receptor structure, wherein the receptor structure is configured to interact with an intracellular or intravesicular component of a biomolecule interaction to be detected, and wherein the extracellular or extravesicular binding structure is configured to bind to a membrane recognition element arranged along a plurality of predetermined lines of the biomolecule detection device.

The present invention relates to engineered SIRP alpha variants and methods of use thereof. Signal regulatory protein a (SIRPa) is a regulatory membrane glycoprotein of the SIRP family. The protein is mainly expressed by bone marrow cells and also expressed by stem cells or neurons. SIRPa is used as an inhibitory receptor and interacts with a widely expressed transmembrane protein CD47. The present disclosure relates to engineered SIRPa variants and methods of use thereof.

The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins, and nucleic acids encoding the chimeric proteins having a first domain comprising an extracellular domain of a first transmembrane protein, a first secreted protein, or a first membrane-anchored extracellular protein and a second domain comprising an extracellular domain of a second transmembrane protein, a second secreted protein, or a second membrane-anchored extracellular protein, in which either or both of the first domain and the second domain decreases self-directed immune system activity when bound to its ligand / receptor. Accordingly, the present disclosure find use in the treatment of autoimmune diseases, and particularly, inflammatory bowel diseases.

The invention relates to bacillus subtilis as well as a construction method and application thereof, and the bacillus subtilis is a gram-positive bacterium from soil, also belongs to one kind of probiotics, and has multiple benefits to a human body. The Irisin is a novel muscle factor which is generated by shearing a transmembrane fibronectin type III domain protein 5 (fibronectin type III domain-conforming protein 5, FNDC5) through a proteolytic enzyme, and has the effects of alleviating obesity, improving insulin resistance, resisting inflammation and the like. According to the invention, a strain of bacillus subtilis capable of expressing human active irisin is constructed, and meanwhile, a probiotic oral embedding method is provided, so that the in-vivo activity and effect of the bacillus subtilis are improved. The expression strain not only can express and produce the tectoridin protein with activity and without endotoxin, but also can exert the activity of probiotics through oral administration after embedding.

The invention belongs to the technical field of biological medicine, and discloses application of JAM3 protein in preparation of a medicine for inhibiting formation of a neutrophil extracellular trapping net. JAM3 is an I-type single transmembrane protein containing 310 amino acids, and belongs to an immunoglobulin superfamily. Researches show that the JAM3 protein remarkably inhibits excessive formation of a sepsis neutrophile granulocyte extracellular trapping net by regulating and controlling an activation path of neutrophile granulocytes, and meanwhile prevents blood platelets from being excessively captured, so that formation of microthrombus in the liver and damage to organs are avoided, disease progression is effectively controlled, and recovery of peripheral blood cells and organisms is promoted.

The application provides a high-purity human Orai2 membrane protein preparation method based on a mammalian cell expression system. The method obtains a recombinant expression vector containing a human Orai2 gene and an affinity tag sequence; the recombinant expression vector is transfected into a host cell line for expression; a membrane dissolving buffer containing dodecyl-beta-D-maltopyranoside and cholesteryl hemisuccinate is used for lysis extraction of the host cell; after centrifugation to obtain supernatant, the supernatant is sequentially separated and purified by using an affinity chromatography medium and a gel exclusion chromatography medium, and high-purity human Orai2 protein is obtained. The application constructs a thermodynamic equilibrium micellar microenvironment, solves the conformational inactivation problem in the extraction process of multiple transmembrane proteins, and realizes efficient and high-purity enrichment of human Orai2 protein.

Providing an adapter polypeptide and a method for using it. [Solution] Compositions of extracellular vesicles, as well as methods and systems for producing extracellular vesicles, are described herein. Methods for using extracellular vesicles are also described herein. This disclosure provides extracellular vesicles designed to target a wide variety of cell types, including different cells and organs in the body, as well as cells associated with disease or disorder. In some cases, the extracellular vesicles provided herein can be readily modified to bind specifically to a target. For example, they may include an extracellular domain that binds to a cell surface marker (e.g., the extracellular domain of a transmembrane protein within the membrane of the extracellular vesicle). Generally, the extracellular vesicles provided herein include an adapter polypeptide having an extracellular domain and, optionally, a transmembrane domain that binds to a cell surface marker.

The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and / or the cytokine-based T-cell activating transmembrane protein.

The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

The invention provides an anti-SLC6A8 antibody or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, provided is an anti-SLC6A8 antibody or an antigen binding fragment thereof, which is capable of effectively binding to human SLC6A8 transmembrane protein. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment, and the antibody drug conjugate can be applied to preparation of drugs for treating overexpression SLC6A8 diseases, and has a good application prospect.

To provide methods for degrading target surface proteins in the ubiquitin pathway using bispecific binding agents or immunoconjugates that bind to the target surface proteins and membrane-bound ubiquitin E3 ligase.SOLUTION: The present invention relates, inter alia, to methods of degrading target surface proteins in the ubiquitin pathway using bispecific binding agents or immunoconjugates that bind to target surface proteins and membrane-bound ubiquitin E3 ligase. The present invention also relates to methods of degrading target surface proteins in the ubiquitin pathway using engineered membrane spanning proteins that bind to target surface proteins and exhibit ubiquitin E3 ligase activity. The present disclosure also provides compositions and methods useful for making bispecific binding agents and engineered transmembrane proteins, immunoconjugates, nucleic acids encoding them, host cells genetically modified with said nucleic acids, and methods of modulating the activity of cells and / or treating various diseases, such as cancer.SELECTED DRAWING: Figure 1

The invention discloses a transmembrane protein 16F and application of a gene coded by the transmembrane protein 16F as a target spot in preparation of a medicine for regulating and controlling tumor ferroptosis. The tumor is any one of lymphoma, melanoma, colon cancer, cervical cancer, fibrosarcoma and ovarian epithelial cancer. The invention finds that TMEM16F is a ferroptosis inhibiting factor which does not change a cell lipid peroxidation process, and shows that the spatial distribution of oxPLs can regulate ferroptosis. In the ferroptosis process, the TMEM16F-mediated phospholipid overturning process is activated, and the effect of regulating and controlling phospholipid redistribution is achieved. In addition, the combination of TMEM16F defect and anti-PD-1 treatment shows a synergistic anti-tumor effect, and initiates a strong tumor immunological rejection reaction. The ivermectin has the biological activity of inhibiting the overturning function of TMEM16F phospholipid, and the inhibition effect of the ivermectin on TMEM16F effectively enhances the reactivity of anti-PD-1 treatment.

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

Disclosed are methods for obtaining cells that express antibodies that bind transmembrane proteins, methods for generating antibodies from such cells, antibodies to transmembrane proteins and fragments thereof, and nucleic acids encoding the antibodies. More particularly, the disclosure relates to methods for obtaining antibody-producing cells that express an antibody that binds to a transmembrane protein based on the use of lipid bilayer-membrane scaffold protein complexes to present transmembrane protein antigens to cells.

The present invention provides a central nervous system targeted pharmaceutical composition that can be used to treat various forms of brain damage, wherein an integrin antibody is attached to a transmembrane protein of an exosome through genetic engineering, and said exosome is used as a carrier to encapsulate a therapeutic drug.